Q-omics provides the consensus-scored PPIAL4E profile across patient tissues and cancer cell-line models. PPIAL4E expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PPIAL4E is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, PPIAL4E RNA expression shows 6,264 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight MESO, HNSC, and BRCA as cancer lineages where PPIAL4E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPIAL4E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPIAL4E survival associations across molecular data types. PPIAL4E RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPIAL4E RNA expression–survival associations across cancer types. High PPIAL4E expression shows unfavorable associations in MESO, COAD, ACC, UVM, CHOL and THCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .016). Together, the overview and detailed table identify MESO as the clearest survival context for PPIAL4E RNA expression.
This table summarizes PPIAL4E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for PPIAL4E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPIAL4E shows lower tumor expression in PRAD and higher tumor expression in HNSC, BRCA, ESCA and LUSC. The HNSC box plot shows higher PPIAL4E RNA expression in tumor versus normal tissue (log2 FC = +0.063, t-test p = .017).
This table shows molecular features associated with PPIAL4E in patient tissues and cancer cell lines. In patient samples, PPIAL4E shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, PPIAL4E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE.
